G:MILAssicurazioni Generali S.p.A. Analysis
Data as of 2026-03-10 - not real-time
€33.59
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Assicurazioni Generali trades at €33.59, well below its DCF‑derived fair value of €39.77, implying roughly a 9‑15% upside. The stock’s P/E of 13.3 is comfortably under the industry average of 17.4, and it delivers a robust 4.35% dividend yield with a moderate 56% payout ratio, underscoring cash‑flow strength. Technicals show a bullish trend direction, a 20‑day SMA (34.91) just above the 50‑day SMA (34.87), but the price sits below both, while the MACD remains bearish and the RSI at 40 suggests limited downside pressure. The volatility of 23.3% over the past 30 days is moderate, and a low beta (~0.37) points to limited market‑wide risk, supported by increasing volume trends.
The upcoming merger of Generali’s asset‑management arm could act as a catalyst, enhancing fee income and cross‑selling opportunities. Fundamental metrics reveal 5.6% revenue growth, a healthy 13% ROE, and strong operating cash flow that comfortably covers its €38.7 bn debt despite a high debt‑to‑equity ratio, thanks to €8.8 bn in cash. Combined with diversified geographic exposure and a solid dividend profile, the stock appears positioned for medium‑ to long‑term appreciation.
The upcoming merger of Generali’s asset‑management arm could act as a catalyst, enhancing fee income and cross‑selling opportunities. Fundamental metrics reveal 5.6% revenue growth, a healthy 13% ROE, and strong operating cash flow that comfortably covers its €38.7 bn debt despite a high debt‑to‑equity ratio, thanks to €8.8 bn in cash. Combined with diversified geographic exposure and a solid dividend profile, the stock appears positioned for medium‑ to long‑term appreciation.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bearish MACD histogram indicating short‑term momentum weakness
- Price trading below short‑term moving averages
- Potential catalyst from asset‑management merger pending
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Undervalued relative to DCF and industry multiples
- Attractive dividend yield with sustainable payout
- Solid earnings growth and improving forward EPS
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Low beta and diversified global exposure reduce systematic risk
- Strong cash generation supporting debt service and dividend
- Strategic merger enhancing asset‑management scale and fee income
Key Metrics & Analysis
Financial Health
Revenue Growth5.60%
Profit Margin6.73%
P/E Ratio13.3
ROE13.39%
ROA0.90%
Debt/Equity119.75
P/B Ratio1.7
Op. Cash Flow€18.8B
Free Cash Flow€5.1B
Industry P/E17.4
Technical Analysis
TrendBullish
RSI40.1
Support€32.06
Resistance€36.48
MA 20€34.91
MA 50€34.87
MA 200€33.28
MACDBearish
VolumeIncreasing
Fear & Greed Index78
Valuation
Fair Value€39.77
Target Price€36.75
Upside/Downside9.40%
GradeUndervalued
TypeBlend
Dividend Yield4.35%
Risk Assessment
Beta0.37
Volatility23.30%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.